213684-61-8

Basic information

• Product Name: N-(2,6-diisopropylphenyl)-6-(oxazolo[5,4-b]pyridin-2-ylthio)hexanamide
• Synonyms: N-(2,6-diisopropylphenyl)-6-(oxazolo[5,4-b]pyridin-2-ylthio)hexanamide
• CAS NO: 213684-61-8
• Molecular Weight: 425.595
• Mol File: 213684-61-8.mol

Chemical Properties

• CAS DataBase Reference: N-(2,6-diisopropylphenyl)-6-(oxazolo[5,4-b]pyridin-2-ylthio)hexanamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2,6-diisopropylphenyl)-6-(oxazolo[5,4-b]pyridin-2-ylthio)hexanamide(213684-61-8)
• EPA Substance Registry System: N-(2,6-diisopropylphenyl)-6-(oxazolo[5,4-b]pyridin-2-ylthio)hexanamide(213684-61-8)

Safety Data

• Hazardous Substances Data: 213684-61-8(Hazardous Substances Data)

Upstream product

• 24544-04-5 2,6-diisopropylbenzenamine 
• 4224-70-8 6-bromohexanoic acid 
• 199592-72-8 6-bromo-N-(2,6-diisopropylphenyl)hexanamide 
• 169205-99-6 2-Mercaptooxazolo<5,4-b>pyridine 

Relevant articles and documents

Design, synthesis and pharmacology of aortic-selective acyl-CoA: Cholesterol O-acyltransferase (ACAT/SOAT) inhibitors

We describe our molecular design of aortic-selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT, also abbreviated as SOAT) inhibitors, their structure–activity relationships (SARs) and their pharmacokinetic (PK) and pharmacological profiles. The connection of two weak ligands—N-(2,6-diisopropylphenyl)acetamide (50% inhibitory concentration [IC50] = 8.6 μM) and 2-(methylthio)benzo[d]oxazole (IC50 = 31 μM)—via a linker comprising a 6 methylene group chains yielded a highly potent molecule, 9-(benzo[d]oxazol-2-ylthio)-N-(2,6-diisopropylphenyl)nonanamide (3h) that exhibited high potency (IC50 = 0.004 μM) toward aortic ACAT. This head-to-tail design made it possible to markedly enhance the activity to 2150- to 7750-fold and to discriminate the isoform-selectivity based on the double-induced fit mechanism. At doses of 1 and 3 mg/kg, 3h significantly decreased the lipid-accumulation areas in the aortic arch to 74 and 69%, respectively without reducing the plasma total cholesterol level in high fat- and cholesterol-fed F1B hamsters. Here, we demonstrate the antiatherosclerotic effect of 3h in vivo via its direct action on aortic ACAT and its powerful modulator of cholesterol level. This molecule is a potential therapeutic agent for the treatment of diseases involving ACAT-1 overexpression.

Anilide compounds and drugs containing the same

The invention relates to a novel anilide compound and a pharmaceutical composition comprising the same. The invention relates to a compound represented by the following general formula: represents a divalent residue of benzene with a substituent(s), heterocycle-condensed benzene which may or may not have a substituent, pyridine which may or may not have a substituent, cyclohexane or naphthalene or Ar represents an aryl group which may or may not have a substituent; X represents —NH—, oxygen atom or sulfur atom; Y represents —NR4—, oxygen atom, sulfur atom, sulfoxide or sulfone; Z represents single bond or —NR5—; R4represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; R5represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; and n represents an integer of 0 to 15. The inventive compounds are useful in the form of pharmaceutical composition, specifically as acyl coenzyme A cholesterol acyltransferase (ACAT) inhibitor.